Pharmaceuticals, Biotechnology and Life Sciences
Sustained normalization and further decreased levels of CSF glycosaminoglycan heparan sulfate, a key CNS disease biomarker, observed after three months…
– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time – SOUTH SAN FRANCISCO,…
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…
Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II)…
Proprietary and differentiated Transport Vehicle (TV) technology shows potential to solve the BBB challenge by delivering biotherapeutics to the brain…
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…
— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time — SOUTH SAN FRANCISCO, Sept. 30, 2020 (GLOBE NEWSWIRE)…
— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time — SOUTH SAN FRANCISCO, Sept. 30, 2020 (GLOBE NEWSWIRE)…